ArticleInternational journal of nephrology2011
Resident stem cells and renal carcinoma.
Article in International journal of nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- SMAD4 Expression in Renal Cell Carcinomas Correlates With a Stem-Cell Phenotype and Poor Clinical Outcomes.Frontiers in oncology · 2021Article
- IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.The Journal of pathology · 2019Article
- Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells.Oncotarget · 2018Article
- Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.Oncotarget · 2017Article
- Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.BMC immunology · 2017Article
- Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.Journal of cancer research and clinical oncology · 2017Article
- Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.Oncotarget · 2016Article
- [Molecular biological foundation of targeted therapy for metastatic renal cell carcinoma].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Review
- Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells.Frontiers in pharmacology · 2016Review
- The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis.Stem cell reviews and reports · 2015Review
- Metastasis-Initiating Cells in Renal Cancer.Current signal transduction therapy · 2014Article
- Progenitor/stem cells in renal regeneration and mass lesions.International urology and nephrology · 2014Review
- Targeted therapy for renal cell carcinoma: The next lap.Journal of carcinogenesis · 2014Review
- Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the cancer stem cell hypothesis tumors are maintained by a cancer stem cell population which is able to initiate and maintain tumors. Tumor-initiating stem cells display stem or progenitor cell properties such as self-renewal and capacity to re-establish tumors that recapitulate the tumor of origin. In this paper, we discuss data relative to the presence of cancer stem cells in human renal carcinoma and their possible origin from normal resident stem cells. The cancer stem cells identified in human renal carcinomas are not derived from the normal CD133(+) progenitors of the kidney, but rather from a more undifferentiated population that retains a mesenchymal phenotype. This population is able to self-renewal, clonogenicity, and in vivo tumor initiation. Moreover, they retain pluripotent differentiation capability, as they can generate not only the epithelial component of the tumor, but also tumor endothelial cells. This suggests that renal cancer stem cells may contribute to the intratumor vasculogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.